AMT has developed Glybera as a gene therapy for sufferers with this disease.

AMT inks contract with Progenika Biopharma for development of LPLchip Amsterdam Molecular Therapeutics and Progenika Biopharma announced today that the firms have entered right into a advancement and commercialization contract for LPLchip, a diagnostic device to rapidly diagnose individuals with complete and partial lipoprotein lipase deficiency . AMT has developed Glybera as a gene therapy for sufferers with this disease. In June of this year AMT announced fresh clinical data showing a one-time administration of its lead product Glybera results in significant long-term health advantages for LPLD individuals . Long-term follow-up data from two scientific trials with comprehensive LPLD patients present that Glybera therapy outcomes in a substantial and clinically important reduction in severe pancreatitis, the most debilitating complication of the disease.

The breadth of our value-added services shall position us to compete for new outsourced physician contracts, health system partnerships and payer relationships. It will allow us to collaborate with our ASC physician companions to pursue the effective and natural integration of medical procedures with anesthesia. It also bolsters our inner competencies thereby enhancing our response to emerging marketplace trends that touch doctor engagement versions, payment model reform and fresh care delivery invention. Mr. Holden continued, AMSURG has a long history of evolving its business to meet up the changing needs of the healthcare sector, and we believe this represents a natural next step. Ultimately, the combination brings together two best in course organizations with tenured management teams, a shared commitment to physician-centric cultures and proved track records for high quality services and patient satisfaction.